Drug intelligence / Profile preview

GKIND007A

Development stage: Preclinical
Lead developer: China Resources Guokang Pharmaceutical
Modality: Small Molecules

Overview

GKIND007A is a preclinical-stage small molecule inhibitor developed by China Resources Guokang Pharmaceutical. It is designed as a broad-spectrum antiviral agent that targets viral RNA polymerase, an essential enzyme for the replication of various viral genomes. By inhibiting this polymerase, the drug aims to suppress viral replication across a wide range of pathogens. GKIND007A is currently positioned as a preclinical candidate for the treatment of broad-spectrum viral infections.

Targets

RNAP (Bacterial dna-dependent RNA polymerase)

Beyond the preview

Go deeper on GKIND007A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND007A.

Explore the full profile